|
Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. |
|
|
Consulting or Advisory Role - Gilead Sciences; Roche Pharma AG |
Travel, Accommodations, Expenses - Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Roche Pharma AG |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Janssen; Pfizer |
|
|
Other Relationship - Medupdate |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche; Takeda |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Novartis; Roche; Spectrum Pharmaceuticals |
Research Funding - Amgen; Roche; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Amgen; Roche |